



PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 66208

Title: Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Reviewer's code: 05464548

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Research, Research Associate, Research Scientist

Reviewer's Country/Territory: Iran

Author's Country/Territory: Sweden

Manuscript submission date: 2021-03-23

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-26 06:48

Reviewer performed review: 2021-07-06 03:36

Review time: 9 Days and 20 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Dear Authors, Thanks for your valuable paper with focusing on PC therapy. As you know these days, whole of the world focused on the NM therapy regarding ¹⁷⁷Lu-PSMA-617 or alpha therapy. Therefore, it seems that the future treatment of the PC will be these ways. I would like to share you these comments for your reference;

1.Docetaxel and ADT have been strongly recommended by oncological guidelines since 2016, particularly for high-volume mHSPC. Even though CHAARTED and GETUG-15 strongly indicates that only high-volume disease patients benefit from the addition of docetaxel to ADT, the impact of metastatic burden has been debated. 2.Overall, we found that patients managed in clinical practice were older and had higher PSA values, poorly differentiated PCa more frequently, and a higher metastatic burden than patients included in clinical trials. However, the effect of docetaxel for mHSPC patients treated in routine practice appears comparable with the overall efficacy reported in the literature.